IDH1 and fibrosarcoma: As hypothesized, in an IDH-mutant fibrosarcoma (HT1080) mouse model, temozolomide combination with PARG knockout depleted freely available NAD by preventing PAR breakdown, leading to hyperPARylation, NAD sequestration, metabolic collapse and, indeed, significant tumor growth suppression was noted [191].